Pfizer Warns 'Troublesome' Price Hike Investigation Means Legal Uncertainty For Industry

The UK's Competition and Markets Authority has issued a provisional opinion finding that Pfizer and Flynn Pharma charged "excessive and unfair" prices for anti-epileptic phenytoin sodium capsules, rocketing the cost for the NHS. But Pfizer claims that it tried to find a profitable and sustainable way of providing the loss-making drug to the NHS, complaining that the CMA is creating greater legal uncertainty for companies.